



FORM PTO-1449 (REV. 7-80)				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 614.1009		SERIAL NO.: 09/883,842			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Stanley STEIN, et al.					
						FILING DATE: June 18, 2001		GROUP: 1615			
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA										
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO
	AB										
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
DF	AC	R. K. Jain, The next frontier of molecular medicine: Delivery of therapeutics, Nature Medicine Vol. 4: Number 6: 655-657 (1998).									
BF	AD	O. García, R.M. Trigo, M. Dolores Blanco and J. M. Teijón, Influence of degree of crosslinking on 5-fluorouracil release from poly(2-hydroxyethyl methacrylate) hydrogels, Biomaterials, Vol. 15: Number 9: 689-694 (1994).									
	AE										
	AF										
	AG										
	AH										
	AI										
	AJ										
	AK										
	AL										
	AM										
	AN										
	AO										
	AP										
	AQ										
	AR										
	AS										
EXAMINER Blessing Fubara						DATE CONSIDERED 4-10-04					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											




FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 614.1009		SERIAL NO.: 09/883,842		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Stanley STEIN, et al.				
				FILING DATE: June 18, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
								YES NO
	AB							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
BF	AC	T.G. Burke, A.K.Mishra, M.C.Wani, and M.E.Wall, Lipid bilayer partitioning and stability of camptothecin drugs, Biochemistry 32:5352-5364 (1993).						
	AD	B. B. Lundberg. Biologically active camptothecin derivatives for incorporation into liposomes bilayers and lipid emulsions, Anticancer Drug Des., 13:453-461 (1998).						
	AE	S.M. Sugaman, Y. Zou, K. Wasan, K. Poirot, R. Kumi, S. Reddy, and R. Perez-Soler, Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies, Cancer Chemother. Pharmacol. 37:531-538 (1996).						
	AF	B. Ertl, P. Platzer, M. Wirth, and F. Gabor, Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin, J. Control Release 61:305-317 (1999).						
	AG	R. Cortesi, E. Esposito, A. Maietti, E. Menegatti, and C. Nasruzzi, Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion, Int.J.Pharm. 159:95-103 (1997).						
	AH	Y. Sadzuka, S. Hirotsu, and S. Hirota. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11, Cancer Lett., 127:99-106 (1998).						
	AI	S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, J. Control. Release, 59:299-307 (1999).						
	AJ	S.C. Yang and J.B. Zhu. Preparation and characterization of camptothecin solid lipid nanoparticles, Drug Dev. Ind. Pharm., n 28:265-274 (2002).						
	AK	C.D.Conover, A. Pendri, C.Lee, C.W. Gilbert, K.L. Shum, and R.B. Greenwald, Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0-polyethylene glycol ester transport form, Anticancer Res. 17:33613368 (1997).						
	AL	C.D.Conover, R.B. Greenwald, A. Pendri, C.W. Gilbert, and, K.L. Shum, Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker, Cancer Chemother.Pharmacol. 42:407-414 (1998).						
	AM	C.D.Conover, R.B. Greenwald, A. Pendri, and, K.L. Shum, Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs, Anticancer Drug Des 14:499-506 (1999).						
BF	AN	V.R. Caiolfa, M. Zamal, A. Fiorino, E. Frigerio, C. Pellizzoni, R.d'Argy, A. Ghiglieri, M.G. Castelli, M. Farao, E. Present, M. Gigli, F. Angelucci, and A. Suarato, Polymer-bound camptothecin: initial biodistribution and antitumor activity studies, J. Control Release 65:105-119 (2000).						
EXAMINER Blessing Fubara				DATE CONSIDERED 9/10/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 614.1009		SERIAL NO.: 09/883,842	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Stanley STEIN, et al.			
				FILING DATE: June 18, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BF	BC	J.W. Singer, P.De Vries, R. Bhatt, J. Tulinsky, P. Klein, C. Li, L. Milas, R.A. Lewis, and, S. Wallace, Conjugation of camptothecins to poly-(L-glutamic acid), Ann.N.Y.Acad.Sci. 922:136-150 (2000).					
	BD	J.W. Singer, R. Bhatt, J. Tulinsky, K.R. Buhler, E. Heasley, P. Klein, and P. De Vries, Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo, J. Control Release 74:243-247 (2001).					
	BE	P.Tardi, E.Choice, D.Masin, T.Redelmeier, M.Bally, and T.D.Madden, Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models, Cancer Res. 60:3389-3393 (2000).					
	BF	F.J. Sharom, The P-glycoprotein efflux pump: how does it transport drugs?, J. Membr.Biol. 160:161-175 (1997).					
	BG	S.H. Jang, M.G. Wientjes, D. Lu, and J.L. Au., Drug delivery and transport to solid tumors, Pharm. Res., 20:1337-1350 (2003).					
	BH	A.S. Hoffman, Hydrogels for biomedical applications, Advanced Drug Delivery Reviews, 43:3-12 (2002).					
	BI	S.W. Kim, Y.H. Bae, and T. Okano, Hydrogels: swelling, drug loading, and release, Pharm.Res. 9:283-290 (1992).					
	BJ	N.A.Peppas, P. Bures, W. Leobandung, and H. Ichikawa, Hydrogels in pharmaceutical formulations, Eur.J.Pharm.Biopharm. 50:27-46 (2000).					
	BK	R. J. Stenekes, A. E. Loebis, C.M. Fernandes, D.J. Crommelin, and W. E. Hennink. Degradable dextran microspheres for the controlled release of liposomes, Int. J. Pharm., 214:17-20 (2001).					
	BL	K.S. Anseth, A.T. Metters, S.J. Bryant, P.J. Martens, J.H. Elisseeff, and C.N. Bowman, In situ forming degradable networks and their application in tissue engineering and drug delivery, J. Control Release 78:199-209 (2002).					
	BM	X. Huang and C.S. Brazel, On the importance and mechanisms of burst release in matrix-controlled drug delivery systems, J. Control Release 73:121-136 (2001).					
	BN	R. Jeyanthi, B. Nagarajan, and K. P. Rao. Solid tumour chemotherapy using implantable collagen-poly (HEMA) hydrogel containing 5-fluorouracil, J. Pharm. Pharmacol., 43:60-62 (1991).					
	BO	C.J. de Groot, J.A. Cadée, J.W. Kolen, W.E. Hennink, and W. den Otter. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model, Int.J. Cancer, 98:134-140 (2002).					
BF	BP	M. Sřastny, D. Plocova, T. Etrych, K. Ulbrich, and B. Rihova. HPMa-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia, Eur. J. Cancer, 38:602-608 (2002).					
EXAMINER Blessing Fubara				DATE CONSIDERED 9/10/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 614.1009		SERIAL NO.: 09/883,842				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Stanley STEIN, et al.						
				FILING DATE: June 18, 2001		GROUP: 1615				
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA									
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
										YES NO
	CB									
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)										
bf	CC	K.H. Bouhadir, E. Alsberg, and D.J. Mooney. Hydrogels for combination delivery of antineoplastic agents, Biomaterials, 22:2625-2633 (2001).								
	CD	H. Okino, Y. Nakayama, M. Tanaka, and T. Matsuda, In situ hydrogelation of photocurable gelatin and drug release, J. Biomed. Mater. Res. 59:233-245 (2002).								
	CE	N.A. Peppas, K.B. Keys, M. Torres-Lugo, and A.M. Lowman, Poly(ethylene glycol)-containing hydrogels in drug delivery, J. Control Release 62:81-87 (1999).								
	CF	O. Garcia, M.D. Blanco, J.A. Martin, and J.M. Teijon, 5-Fluorouracil trapping in poly(2-hydroxyethylmethacrylate-co-acrylamide) hydrogels: in vitro drug delivery studies, Eur. Polymer Journal 36:111-122 (2000).								
	CG	J.A. Cadee, C.J. de Groot, W. Jiskoot, W. den Otter, and W.E. Hennink, Release of recombinant human interleukin-2 from dextran-based hydrogels, J. Control Release 78:1-13 (2002).								
	CH	W.E. Hennink, O. Franssen, W.N.E. van Dijk-Wolthuis, and H. Talsma, Dextran hydrogels for the controlled release of proteins, J. Control Release 48:107-114 (1997).								
	CI	M. Sen and A. Yakar, Controlled release of antifungal drug terbinafine hydrochloride from poly(N-vinyl 2-pyrrolidone/itaconic acid) hydrogels, Int.J.Pharm. 228:33-41 (2001).								
	CJ	V.Subr, R.Duncan, and J.Kopecek, Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds, J.Biomater.Sci.Polym.Ed 1:261-278 (1990).								
	CK	E.Ruel-Gariepy, G.Lecclair, P.Hildgen, A.Gupta, and J.C.Leroux, Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules, J.Control Release 82:373-383 (2002).								
	CL	A. Paavola, I.Kilpelainen, J. Yliruusi, and P.Rosenberg, Controlled release injectable liposomal gel ibuprofen for epidural analgesia, Int.J.Pharm. 199:85-93 (2000).								
	CM	A.Bochot, E.Fattal, A.Gulik, G.Couarraze, and P.Couvreaur, Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides, Pharm.Res. 15:1364-1369 (1998).								
bf	CN	R.J. Stenekes, A.E. Loebis, C.M. Fernandes, D.J. Crommelin, and W.E. Hennink. Controlled release of liposomes from biodegradable dextran microspheres: a novel delivery concept, Pharm. Res., 17:690-695 (2000).								
EXAMINER Blessing Fulwara				DATE CONSIDERED 9/15/04						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 614.1009		SERIAL NO.: 09/883,842			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Stanley STEIN, et al.					
				FILING DATE: June 18, 2001		GROUP: 1615			
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									YES NO
	DB								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
bf	DC	N.O. Dhoot and M.A. Wheatley. Microencapsulated liposomes in controlled drug delivery: strategies to modulate drug release and eliminate the burst effect, J. Pharm. Sci., 92:679-689 (2003).							
	DD	S.Vemuri and C.T.Rhodes, Preparation and characterization of liposomes as therapeutic delivery systems: a review, Pharm.Acta Helv. 70:95-111 (1995).							
	DE	A. Sharma and U.S.Sharma, Liposomes in drug delivery: progress and limitations, Int.J.Pharm. 154:123-140 (1997).							
	DF	P.Crosasso, M.Ceruti, P.Brusa, S.Apicco, F.Dosio, and L.Cattel, Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes, J.Control Release 63:19-30 (2000).							
	DG	A.Sharma and R.M.Straubinger, Novel taxol formulations: preparation and characterization of taxol-containing liposomes, Pharm.Res. 11:889-896 (1994).							
	DH	S.B.Kulkarni, G.V.Betageri, and M.Singh, Factors affecting microencapsulation of drugs in liposomes, J.Microencapsul. 12:229-246 (1995).							
	DI	S.Vemuri and C.T.Rhodes, Development and characterization of a liposome preparation by a pH-gradient method, J.Pharm.Pharmacol. 46:778-783 (1994).							
	DJ	L.D.Mayer, L.C.Tai, M.B.Bally, G.N.Mitlenes, R.S.Ginsberg, and P.R.Cullis, Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients, Biochim.Biophys.Acta 1025:143-151 (1990).							
	DK	D.B.Fenske, K.F.Wong, E.Mauer, N.Maurer, J.M.Leenhouts, N.Boman, L.Amankwa, and P.R.Cullis, Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients, Biochim.Biophys.Acta 1414:188-204 (1998).							
	DL	S.Clerc and Y.Barenholz, Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients, Biochim.Biophys.Acta 1240:257-265 (1995).							
	DM	T.Llan and R.J.Ho, Trends and developments in liposome drug delivery systems, J.Pharm.Sci. 90:667-680 (2001).							
	DN	H. Talsma and D.J.A. Crommelin, Liposomes as drug delivery systems, Part II: Characterization, Pharm. Tech., 52-58 (1992).							
	DO	H. Talsma and D.J.A.Crommelin, Liposomes as drug delivery systems, Part III: Stabilization, Pharm. Tech., 48-59 (1993).							
	DP	D. Subramanian and M.T. Muller, Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan, Oncol.Res. 7:461-469 (1995).							
bf	DQ	B. Qiu, S. Stefanos, J. Ma, A. Laloo, B.A. Perry, M.J. Leibowitz, P.J. Sinko, and S. Stein, A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery, Biomaterials 24:11-18 (2003).							
EXAMINER Blessing Eubank				DATE CONSIDERED 9/10/04					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									